Aquestive Therapeutics, Inc. (AQST) Current Ratio
- Current ratio · latest quarter: Value 7.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.19× | Current assets / current liabilities. $118.49M ÷ $16.48M ≈ 7.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 118.49M USD | Assets, Current |
| Current obligations | 16.48M USD | Liabilities, Current |
| Cash and equivalents | 98.49M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 7.37M USD | Inventory, Net |
| Payables | 8.96M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $118.49M | $16.48M | $98.49M | (m) | (m) | $7.37M | $8.96M | (m) | 7.19× |
| 2026-03-31 | $130.18M | $31.75M | $110.73M | (m) | (m) | $8.07M | $11.89M | (m) | 4.10× |
| 2025-12-31 | $149.27M | $47.61M | $121.17M | (m) | (m) | $6.17M | $29.86M | (m) | 3.14× |
| 2025-09-30 | $151.67M | $25.57M | $129.06M | (m) | (m) | $7.88M | $10.87M | (m) | 5.93× |
| 2025-06-30 | $81.72M | $23.16M | $60.54M | (m) | (m) | $8.13M | $11.95M | (m) | 3.53× |
| 2025-03-31 | $89.17M | $18.30M | $68.66M | (m) | (m) | $7.20M | $12.28M | (m) | 4.87× |
| 2024-12-31 | $88.22M | $18.86M | (m) | (m) | (m) | $6.04M | $10.29M | (m) | 4.68× |
| 2024-09-30 | $96.57M | $15.15M | $77.89M | (m) | (m) | $7.02M | $7.57M | (m) | 6.37× |
| 2024-06-30 | $104.01M | $13.89M | $89.87M | (m) | (m) | $6.97M | $5.70M | (m) | 7.49× |
| 2024-03-31 | $113.38M | $18.06M | $95.20M | (m) | (m) | $7.73M | $10.52M | (m) | 6.28× |
| 2023-12-31 | $40.97M | $18.31M | (m) | (m) | (m) | $6.77M | $8.93M | (m) | 2.24× |
| 2023-09-30 | $42.46M | $24.06M | $24.92M | (m) | (m) | $7.08M | $9.99M | (m) | 1.76× |
| 2023-06-30 | $39.79M | $38.65M | $22.44M | (m) | (m) | $5.95M | $10.69M | (m) | 1.03× |
| 2023-03-31 | $43.71M | $40.38M | $26.88M | (m) | (m) | $6.98M | $12.44M | (m) | 1.08× |
| 2022-12-31 | $39.89M | $39.53M | (m) | (m) | (m) | $5.78M | $9.95M | (m) | 1.01× |
| 2022-09-30 | $38.09M | $36.56M | $18.65M | (m) | (m) | $6.72M | $11.07M | (m) | 1.04× |
| 2022-06-30 | $43.51M | $29.64M | $17.70M | (m) | (m) | $5.01M | $8.89M | (m) | 1.47× |
| 2022-03-31 | $42.59M | $24.18M | $14.74M | (m) | (m) | $4.63M | $8.50M | (m) | 1.76× |
| 2021-12-31 | $47.26M | $21.96M | (m) | (m) | (m) | $4.04M | $8.31M | (m) | 2.15× |
| 2021-09-30 | $50.21M | $25.04M | $31.16M | (m) | (m) | $2.86M | $6.21M | (m) | 2.01× |
| 2021-06-30 | $51.00M | $23.04M | $34.23M | (m) | (m) | $2.84M | $8.10M | (m) | 2.21× |
| 2021-03-31 | $44.44M | $20.05M | $27.50M | (m) | (m) | $2.80M | $6.69M | (m) | 2.22× |
| 2020-12-31 | $44.63M | $21.10M | (m) | (m) | (m) | $2.46M | $7.09M | (m) | 2.11× |
| 2020-09-30 | $31.68M | $18.37M | $17.06M | (m) | (m) | $3.24M | $9.17M | (m) | 1.72× |
| 2020-06-30 | $43.91M | $14.88M | $25.42M | (m) | (m) | $3.17M | $8.79M | (m) | 2.95× |
| 2020-03-31 | $51.09M | $15.36M | $35.52M | (m) | (m) | $3.09M | $10.28M | (m) | 3.33× |
| 2019-12-31 | $68.31M | $18.55M | $49.33M | (m) | (m) | $2.86M | $12.27M | (m) | 3.68× |
| 2019-09-30 | $38.06M | $20.05M | $20.91M | (m) | (m) | $4.12M | $14.20M | (m) | 1.90× |
| 2019-06-30 | $39.06M | $24.63M | $22.16M | (m) | (m) | $4.65M | $20.03M | (m) | 1.59× |
| 2019-03-31 | $55.96M | $29.64M | $39.93M | (m) | (m) | $5.14M | $19.14M | (m) | 1.89× |
| 2018-12-31 | $74.20M | $32.95M | $60.60M | (m) | (m) | $5.44M | $20.44M | (m) | 2.25× |
| 2018-09-30 | $77.36M | $21.33M | $63.98M | (m) | $7.45M | $4.48M | $12.34M | (m) | 3.63× |
| 2018-06-30 | $26.65M | $23.47M | $10.64M | (m) | $6.63M | $4.35M | $16.52M | (m) | 1.14× |
| 2017-12-31 | $28.16M | $15.35M | $17.38M | (m) | (m) | $4.01M | $9.60M | (m) | 1.83× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |